Tempest Therapeutics, Inc. (TPST) Tops Q2 EPS by 13c
Tweet
Share
E-mailGet Alerts TPST Hot Sheet
Join SI Premium – FREE
Tempest Therapeutics, Inc. (NASDAQ: TPST) reported Q2 EPS of ($0.79), $0.13 better than the analyst estimate of ($0.92).
For earnings history and earnings-related data on Tempest Therapeutics, Inc. (TPST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Green Dot and CommerceOne shareholders approve acquisition deal
- Nike names former Pfizer CFO David Denton as new finance chief
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
